Literature DB >> 35195258

Understanding Drug Sensitivity and Tackling Resistance in Cancer.

Jeffrey W Tyner1,2, Franziska Haderk3,4,5, Anbarasu Kumaraswamy6, Linda B Baughn7, Brian Van Ness8, Song Liu9, Himangi Marathe9, Joshi J Alumkal6, Trever G Bivona3,4,5, Keith Syson Chan10,11, Brian J Druker1,2, Alan D Hutson9, Peter S Nelson12,13, Charles L Sawyers14,15, Christopher D Willey16.   

Abstract

Decades of research into the molecular mechanisms of cancer and the development of novel therapeutics have yielded a number of remarkable successes. However, our ability to broadly assign effective, rationally targeted therapies in a personalized manner remains elusive for many patients, and drug resistance persists as a major problem. This is in part due to the well-documented heterogeneity of cancer, including the diversity of tumor cell lineages and cell states, the spectrum of somatic mutations, the complexity of microenvironments, and immune-suppressive features and immune repertoires, which collectively require numerous different therapeutic approaches. Here, we describe a framework to understand the types and biological causes of resistance, providing translational opportunities to tackle drug resistance by rational therapeutic strategies. ©2022 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Year:  2022        PMID: 35195258      PMCID: PMC9018544          DOI: 10.1158/0008-5472.CAN-21-3695

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  190 in total

1.  Lamarck, evolution, and the inheritance of acquired characters.

Authors:  Richard W Burkhardt
Journal:  Genetics       Date:  2013-08       Impact factor: 4.562

2.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Authors:  Elena Sotillo; David M Barrett; Kathryn L Black; Asen Bagashev; Derek Oldridge; Glendon Wu; Robyn Sussman; Claudia Lanauze; Marco Ruella; Matthew R Gazzara; Nicole M Martinez; Colleen T Harrington; Elaine Y Chung; Jessica Perazzelli; Ted J Hofmann; Shannon L Maude; Pichai Raman; Alejandro Barrera; Saar Gill; Simon F Lacey; Jan J Melenhorst; David Allman; Elad Jacoby; Terry Fry; Crystal Mackall; Yoseph Barash; Kristen W Lynch; John M Maris; Stephan A Grupp; Andrei Thomas-Tikhonenko
Journal:  Cancer Discov       Date:  2015-10-29       Impact factor: 39.397

3.  Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.

Authors:  Andrea Viale; Piergiorgio Pettazzoni; Costas A Lyssiotis; Haoqiang Ying; Nora Sánchez; Matteo Marchesini; Alessandro Carugo; Tessa Green; Sahil Seth; Virginia Giuliani; Maria Kost-Alimova; Florian Muller; Simona Colla; Luigi Nezi; Giannicola Genovese; Angela K Deem; Avnish Kapoor; Wantong Yao; Emanuela Brunetto; Ya'an Kang; Min Yuan; John M Asara; Y Alan Wang; Timothy P Heffernan; Alec C Kimmelman; Huamin Wang; Jason B Fleming; Lewis C Cantley; Ronald A DePinho; Giulio F Draetta
Journal:  Nature       Date:  2014-08-10       Impact factor: 49.962

4.  Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.

Authors:  M Monzó; R Rosell; J J Sánchez; J S Lee; A O'Brate; J L González-Larriba; V Alberola; J C Lorenzo; L Núñez; J Y Ro; C Martín
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

5.  Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.

Authors:  Martin Carroll; Catherine C Smith; Alexander E Perl; Christine M McMahon; Timothy Ferng; Jonathan Canaani; Eunice S Wang; Jennifer J D Morrissette; Dennis J Eastburn; Maurizio Pellegrino; Robert Durruthy-Durruthy; Christopher D Watt; Saurabh Asthana; Elisabeth A Lasater; RosaAnna DeFilippis; Cheryl A C Peretz; Lisa H F McGary; Safoora Deihimi; Aaron C Logan; Selina M Luger; Neil P Shah
Journal:  Cancer Discov       Date:  2019-05-14       Impact factor: 39.397

6.  Re-education of macrophages as a therapeutic strategy in cancer.

Authors:  Joanna Kowal; Mara Kornete; Johanna A Joyce
Journal:  Immunotherapy       Date:  2019-06       Impact factor: 4.196

7.  Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis.

Authors:  Meera Kumarakulasingham; Patrick H Rooney; Sinclair R Dundas; Colin Telfer; William T Melvin; Stephanie Curran; Graeme I Murray
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

8.  Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.

Authors:  Mohammad Fallahi-Sichani; Verena Becker; Benjamin Izar; Gregory J Baker; Jia-Ren Lin; Sarah A Boswell; Parin Shah; Asaf Rotem; Levi A Garraway; Peter K Sorger
Journal:  Mol Syst Biol       Date:  2017-01-09       Impact factor: 11.429

9.  Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.

Authors:  Joshi J Alumkal; Duanchen Sun; Eric Lu; Tomasz M Beer; George V Thomas; Emile Latour; Rahul Aggarwal; Jeremy Cetnar; Charles J Ryan; Shaadi Tabatabaei; Shawna Bailey; Claire B Turina; David A Quigley; Xiangnan Guan; Adam Foye; Jack F Youngren; Joshua Urrutia; Jiaoti Huang; Alana S Weinstein; Verena Friedl; Matthew Rettig; Robert E Reiter; Daniel E Spratt; Martin Gleave; Christopher P Evans; Joshua M Stuart; Yiyi Chen; Felix Y Feng; Eric J Small; Owen N Witte; Zheng Xia
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-18       Impact factor: 11.205

10.  The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.

Authors:  Sunil K Joshi; Tamilla Nechiporuk; Daniel Bottomly; Paul D Piehowski; Julie A Reisz; Janét Pittsenbarger; Andy Kaempf; Sara J C Gosline; Yi-Ting Wang; Joshua R Hansen; Marina A Gritsenko; Chelsea Hutchinson; Karl K Weitz; Jamie Moon; Francesca Cendali; Thomas L Fillmore; Chia-Feng Tsai; Athena A Schepmoes; Tujin Shi; Osama A Arshad; Jason E McDermott; Ozgun Babur; Kevin Watanabe-Smith; Emek Demir; Angelo D'Alessandro; Tao Liu; Cristina E Tognon; Jeffrey W Tyner; Shannon K McWeeney; Karin D Rodland; Brian J Druker; Elie Traer
Journal:  Cancer Cell       Date:  2021-06-24       Impact factor: 38.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.